Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
HUTCHMED (China) Limited focuses on the development and commercialization of innovative cancer therapies in China and globally. Its competitive position is bolstered by a robust pipeline of oncology drugs, including the marketed product fruquintinib, which has shown strong efficacy in treating colorectal cancer.
HUTCHMED generates revenue primarily through the sale of its proprietary oncology drug fruquintinib, which has gained traction in the Chinese market. The company also benefits from strategic partnerships with global pharmaceutical firms, allowing it to leverage shared resources and expertise in drug development.
Approval and commercialization of new oncology drugs in China and other markets
Partnership developments or collaborations with major pharmaceutical companies
Clinical trial results for pipeline products
Market share growth in the oncology segment
Regulatory changes in drug approval processes in China and globally
Technological disruption in drug development methodologies
Intense competition from both local and international oncology drug manufacturers
Potential for generic competition affecting product pricing
Low operating cash flow could limit R&D investment capabilities
Potential liquidity risks if revenue growth does not stabilize
moderate - while healthcare spending is generally resilient, economic downturns can impact patient access to innovative therapies.
Interest rates affect HUTCHMED primarily through the cost of capital for R&D investments. Higher rates could increase financing costs, impacting growth initiatives.
minimal - the company maintains a low debt-to-equity ratio of 0.08, indicating limited reliance on external credit.
growth - investors are likely attracted by the potential for significant revenue growth from innovative oncology therapies.
high - the stock has shown high volatility, with a 1-year return of -27.1%, indicating sensitivity to market and operational developments.
